News | News By Subject | News by Disease News By Date | Search News

Hypertriglyceridemia News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Ligand Pharmaceuticals Inc. (LGND) To Snag Up To $44.5 Million In Licensing Pact     5/15/2014
AstraZeneca PLC (AZN) Gets A Lift In Pfizer Inc. (PFE) Fight As FDA Approves Heart Pill Epanova     5/7/2014
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) and Pronova BioPharma Announce Top-line Results of the Pivotal Phase 3 Clinical Trial of TAK-085 in Japan for Treatment of Hypertriglyceridemia     5/10/2011
Abbott Laboratories (ABT) And AstraZeneca PLC (AZN) Announce Collaboration To Develop And Commercialize CRESTOR(R) And Next-Generation TriCor(R) (ABT-335) Fixed-Dose Combination     7/5/2006
FDA Rejects Public Citizen's Petition For AstraZeneca's (AZN) CRESTOR(R)     3/15/2005
AstraZeneca (AZN) Presents New Data Demonstrating CRESTOR(R) Reduced C-Reactive Protein Levels In African-American Patients     3/9/2005
Abbott Laboratories (ABT) Receives FDA Approval For New Formulation Of TriCor(R) (Fenofibrate) Tablets For The Treatment Of Common Lipid Disorders     11/8/2004
Merck & Co., Inc. (MRK) Release: ZETIA-R- (ezetimibe) Co-Administered With Fenofibrate Provided Complementary Lipid Lowering Efficacy In Mixed Hyperlipidemia Patients; Ezetimibe And Fenofibrate Treatment Well-Tolerated Over 12 Weeks     11/8/2004
Cipher Pharmaceuticals (CC:CLC) Receives Tentative Approval From FDA For CIP-FENOFIBRATE     7/21/2004

News from Around the Web

Press Releases
Akcea Therapeutics Announces Completion Of Enrollment In Phase 3 COMPASS Trial Of Volanesorsen     5/16/2016
Matinas BioPharma's MAT9001 Demonstrates Superiority In Reducing Triglycerides, Lipids, Apolipoproteins And PCSK9 Levels In Head-To-Head Study With Vascepa     6/15/2015
Matinas BioPharma Provides Update On Clinical Development Program For MAT9001 Following FDA Feedback On IND Submission     12/23/2014
Matinas BioPharma Receives Authorization From Health Canada To Initiate Human Clinical Study Of Lead Product Candidate MAT9001     10/29/2014
Matinas BioPharma Submits Investigational New Drug Application For Lead Product Candidate MAT9001 For The Treatment Of Severe Hypertriglyceridemia     10/20/2014
Catabasis Pharmaceuticals, Inc. To Present CAT-2003 Data At Upcoming Lipid Conferences     4/25/2014
Catabasis Pharmaceuticals, Inc. Initiates Phase 2 Trial Of CAT-2003 In Patients With Severe Hypertriglyceridemia     12/5/2013
Amarin Corporation PLC (AMRN) to Host Conference Call on October 16, 2013 to Discuss Results of FDA Advisory Committee Meeting on ANCHOR Supplemental New Drug Application (sNDA) for Vascepa®     10/9/2013
Acasti Pharma Announces Positive Phase II Open Label Clinical Trial Results     8/13/2013
Amarin Corporation PLC (AMRN) Informed by FDA of October 16th Advisory Committee Date in Connection With Supplemental New Drug Application (sNDA) for Vascepa® in the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia     6/19/2013
Amarin Corporation PLC (AMRN) Announces FDA Advisory Committee Will Not Be Scheduled in Connection With New Drug Application for AMR101     2/13/2012
Acasti Pharma Announces the Initiation of a Second Phase II Clinical Study and Consolidation of Its IP Position     12/5/2011
Acasti Pharma Receives Health Canada Clearance for an Open-Label Phase II Hypertriglyceridemia Trial     10/17/2011
Amarin Corporation PLC (AMRN) Announces NDA Submission for AMR101 for the Treatment of Patients With Very High Triglycerides     9/26/2011
Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia     8/15/2011